H. Lundbeck A/S

HLUN B

Equity

ISIN DK0061804770 / Valor 119252587

Nasdaq Copenhagen Equities (2024-11-19)

DKK 43.74+0.46%

H. Lundbeck A/S
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

H. Lundbeck A/S is a globally recognized pharmaceutical company headquartered in Denmark, with a specialized focus on developing treatments for brain diseases. Founded over a century ago by Hans Lundbeck, the company has grown to employ approximately 5,500 individuals worldwide and operates in more than 50 countries. Lundbeck's commitment to neuroscience has led to the creation of innovative therapies that address a range of conditions, including neurology and psychiatry disorders such as Alzheimer's disease, depression, and schizophrenia. The company's products are registered in over 100 countries, reaching more than 8 million people daily. With a strong foundation in research and development, Lundbeck continues to contribute significantly to the field of brain health, supported by its largest shareholder, the Lundbeck Foundation, which dedicates substantial resources to medical research.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

H. Lundbeck A/S reported a revenue increase of 7% at constant exchange rates (CER) and 5% in Danish Krone (DKK), reaching DKK 5,288 million in the first quarter of 2024. This growth was primarily driven by strong performances in the U.S. and European markets.

Strategic Brands Performance

The revenue from H. Lundbeck A/S's strategic brands grew by 17% CER and 15% DKK, totaling DKK 3,759 million in Q1 2024. These brands now represent 71% of the company's total revenue, with notable contributions from Brintellix®/Trintellix®, Rexulti®, Abilify Maintena®/Asimtufii, and Vyepti®.

Adjusted EBITDA

Adjusted EBITDA for H. Lundbeck A/S decreased to DKK 1,746 million, reflecting a 2% decline at CER and a 5% decline in DKK. This decrease was attributed to lower adjusted gross margins and increased R&D costs to support ongoing pipeline projects and targeted investments in sales and promotion.

Earnings Per Share

H. Lundbeck A/S reported an adjusted earnings per share (EPS) of DKK 1.38 for the first quarter of 2024, marking a 1% increase. The underlying growth in adjusted EBITDA, excluding stock valuation fluctuations, was 6% CER, resulting in a slight decrease in the adjusted EBITDA margin by 0.6 percentage points.

Financial Outlook

H. Lundbeck A/S maintained its financial guidance for 2024, expecting revenue growth of 7% to 10% at CER and adjusted EBITDA growth of 10% to 16% at CER. This outlook underscores the company's confidence in its strategic initiatives and market performance for the remainder of the year.

Summarized from source with an LLMView Source

Key figures

27.2%1Y

%3Y

%5Y

Performance

24.4%1Y

29.1%3Y

29.1%5Y

Volatility